- Home
- EQS vs ALLR Comparison
EQS vs ALLR Comparison
Compare EQS & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- ALLR
- Stock Information
- Founded
- EQS 1991
- ALLR 2004
- Country
- EQS United States
- ALLR United States
- Employees
- EQS N/A
- ALLR N/A
- Industry
- EQS Finance Companies
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- ALLR Health Care
- Exchange
- EQS Nasdaq
- ALLR Nasdaq
- Market Cap
- EQS 13.9M
- ALLR 13.3M
- IPO Year
- EQS N/A
- ALLR N/A
- Fundamental
- Price
- EQS $1.38
- ALLR $1.00
- Analyst Decision
- EQS
- ALLR
- Analyst Count
- EQS 0
- ALLR 0
- Target Price
- EQS N/A
- ALLR N/A
- AVG Volume (30 Days)
- EQS 13.5K
- ALLR 464.0K
- Earning Date
- EQS 01-01-0001
- ALLR 08-04-2025
- Dividend Yield
- EQS N/A
- ALLR N/A
- EPS Growth
- EQS N/A
- ALLR N/A
- EPS
- EQS N/A
- ALLR N/A
- Revenue
- EQS $1,329,000.00
- ALLR N/A
- Revenue This Year
- EQS N/A
- ALLR N/A
- Revenue Next Year
- EQS N/A
- ALLR N/A
- P/E Ratio
- EQS N/A
- ALLR N/A
- Revenue Growth
- EQS 152.66
- ALLR N/A
- 52 Week Low
- EQS $0.74
- ALLR $0.61
- 52 Week High
- EQS $1.52
- ALLR $7.45
- Technical
- Relative Strength Index (RSI)
- EQS 67.89
- ALLR 54.51
- Support Level
- EQS $1.30
- ALLR $0.80
- Resistance Level
- EQS $1.39
- ALLR $1.09
- Average True Range (ATR)
- EQS 0.05
- ALLR 0.07
- MACD
- EQS -0.00
- ALLR 0.02
- Stochastic Oscillator
- EQS 94.74
- ALLR 63.03
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.